The variation between Angiotensin-Converting Enzyme Inhibitors (A.C.E. Inhibitors) and Angiotensin II Receptors Antagonists (A.II R.A.), in C.O.P.Ds. and Hypertensive patients

  • Jawad F. H. Al-Musawi


This study reflects that both A.C.E. inhibitors and A.IIR.A. had been reduced the hypertension in  a total 281 patients, that A.C.E. inhibitors had significant results 175(62.27%), more than  A.IIR.A. 106(27.72%) in treatment of hypertension in those C.O.P.D. patients with ages ranged between (40-70) years old. Also, we found that there was some degree of serum lipids reduction in those patients which were treated by either A.C.E. inhibitors 22(8.185%), or  by A.IIR.A.24(8.540%), with no significant different results in this reduction of serum lipids in both A.C.E. inhibitors and A.IIR.A..


-Laurence D.R., Bennett P.N. et al, Clinical Pharmacology, "Sulphonamide and sulphonamide combination" (Churchill Ling stone), 9th Ed. 2003, 137.

- Mary J. Mycek, Richard A. Harvey, et al, "Lippincott's illustrated Reviews, uses of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Antagonist", 2nd Ed, 1997, 156-157, 187.

-Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, The trial of treatment of heart failure in with A.T.1 blockers ,"Clinical study ,randomized trail"; Lancet, 1999;353;611-16.

- Cooper ME., "Pathogenesis, Prevention, and treatment of diabetic nephropathy"; Lancet; 1998; 352; 213-219.

-Lyme J. babanor F., Awerian J., Kemory I. et al; "The side effects of ACE inhibitors and angiotensin 2 receptor antagonist in different population"; BMJ;1999;Vol.213; issue 8077; 132-145.

-Defar M., Sawyer D., Jonson S., et al, The risky adverse effect of ACE inhibitors and β-blockers" M.E.P.P.O;, 2011; 664-667.

--Mary J. Mycek, Richard A. Harvey, et al,Lippincotts illustrated reviews pharmacology, "Antihypertensive drugs, 2nd Ed. 1997, 179.

--Leonard G. Gomella, Steen A. Hasit, Aimee G. Adams, "Clinician Pocket Drugs Reference" –Copyright Ed., 2011, 146 and 161.

- Spence J.D., Westlie M. R. Breslow J.L. et al; Pathogenesis of atherosclerosis and its complications. effects of antihypertensive drugs, J Hum Hyper tens 3 1989 63-68.

-Becaterina R., Basta G., Schulz et all, The incidence of A.C.E. inhibitors in Chronic obstructive pulmonary disease patients, British journal of pharmacology; vol. 325;2012; 204-10.

- Keane WF, Kasiske BL, O'Donnell MP: Hyperlipidemia following induction of metabolic disorders in animals with different, that deal with different antihypertensive agents; Am J.

-Mark K., John L., et al" Serum lipids a analysis after treatment with different types of antihypertensive agents" British journal of pharmacology, 1998, Vol. 218, 96-152.

-Keider S., Smith J., Breslow J.L., et al "The angiotensin 11 receptor antagonist, Losartan, inhibit LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice, Biochem Biophys Res Commun 236, 1997, 622-625.

- Spence J.D., Westlie M. R. Breslow J.L., Namelon K., et al,"The role of β-blockers or ACE inhibitors and angiotensin II antagonist for reduction of serum lipid, in atherosclerotics", BMJ,Vol.325, 1999, issue 801, 201-2.